Genmab — Maj 2018

[Bulder]

Jo, flere pts i tecentriq studiet var under overvejelse.

[Solsen]

Tak og det er vel så ikke for at de ikke har set virkning

[Bulder]

næppe

[Sukkeralf]

Bulder jeg så det godt, men mener at det har været nævnt tidligere - der kører stadig kun et studie med GSK2857916, men primær endpoint er her i juni/juli eller så

[Bulder]

Men en konkurrent er pludselig blevet en partner.

[Sukkeralf]

Ja vel begge dele, for de kører formentlig ikke kun kombier med Dara

[Solsen]

Roche kunne være oplagt - Genmab kunne ramme dem med hårdt CD20/CD3 og en lind strøm af penge fra Arzerra og Darzalex er jo ikke at kimse af. De vil ikke få lov til at være partner på CD20/CD3 - det ville være et kommercielt selvmål af Genmab.

[E_L]

see the answer to Anderson from Jyske; Jan points at Dara as ideal combination drug as he has done in the past

[Bulder]

Der er vist flere, der er ved at løbe tør for patenter, som kunne være interesseret. Men kan ikke være noget på bedding, siden Gen kører sådan på med udvikling af salgsafdeling.

[Sukkeralf]

Angående solide og flere patienter: "We also have possibilities of expanding that study by adding in more patients. And I think that’s up to Janssen to see whether they do that. And we have just recently started interacting with Janssen about what level of detail we can potentially use in the first communication in the second half of this year. And that will likely include in different subsets of patients because we’re doing a lot of biomarker analysis in that study, looking at overall response"

[E_L]

So HuMax AXL ADC now is lung cancer, melanoma and sarcoma ; did we know that already?

[Solsen]

It was published on clinical trials weeks ago

[E_L]

ok. i have to start writing things down, it is too much to remember these days...

[Solsen]

Only Sarcoma was new https://clinicaltrials.gov/ct2/history/NCT02988817?A=5&B=6&C=Side-by-Side

[Solsen]

We all have problems to hold on. A lot is goin on and it will increase over time.

[bibob]

Sagsanlæg Morphosys. https://medwatch.dk/secure/Medicinal___Biotek/article10586602.ece

[Bulder]

11.24 skrev jeg SH-tal 23. juni. Det er 23. maj og så igen 20. juni.

[E_L]

@Bibob ; just curious; is that news from today, or is Medwatch just reporting it today...? (and did they add that Jan yesterday said that the majority of any potential costs would be taken by Janssen ?)

[Solsen]

He said that on cc yesterday

[Helge_LarsenPI-redaktør]

http://www.proinvestor.com/investornyt/526796/genmab-boss-om-gylden-mulighed-i-usa-janssens-haer-kan-gore-det-igen